Brind.
  1. Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
  2. Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.

Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.

1 report, 1 independent Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.

Who's involved

What this event is mainly about
Bristol-Myers SquibbAstraZeneca

Keep exploring

Part of

Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.

Also in this story

All 3 developments

Within Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.

The entities involved

Related events

Coverage

Newest first; wire copies grouped